Praful Bohra, senior research analyst for pharmaceuticals at Nirmal Bang Institutional Equities, talks about a few developments in the pharma sector and says that the space ideally should be part of a portfolio even in a rising market. He says Lupin and Ranbaxy are done with selloffs with and one can look at buying Ipca Labs in the mid-cap space.